Zhejiang Yatai Pharmaceutical Co Ltd
SZSE:002370
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (133.3), the stock would be worth ¥2.45 (64% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 366.4 | ¥6.74 |
0%
|
| 3-Year Average | 133.3 | ¥2.45 |
-64%
|
| 5-Year Average | 79.3 | ¥1.46 |
-78%
|
| Industry Average | 23.8 | ¥0.44 |
-94%
|
| Country Average | 20.8 | ¥0.38 |
-94%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Zhejiang Yatai Pharmaceutical Co Ltd
SZSE:002370
|
5B CNY | 366.4 | 37.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 50.8 | 39.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 23.2 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 21 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 15.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 18.5 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 10.6 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 17.1 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 10.5 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
Zhejiang Yatai Pharmaceutical Co Ltd
Glance View
Zhejiang Yatai Pharmaceutical Co., Ltd. engages in the research, manufacture & distribution of drugs. The company is headquartered in Shaoxing, Zhejiang and currently employs 584 full-time employees. The company went IPO on 2010-03-16. The firm's main business consists of the research, development, production and sales of chemical agents, chemical raw materials and diagnostic reagents, as well as the provision of pharmaceutical research and development outsourcing (CRO) services. The Company’s chemical agents are classified as antibiotics and non-antibiotic drugs. Along with its subsidiaries, the Company provides preclinical research services, clinical research services and other advisory services. The firm distributes its products primarily in domestic markets and overseas markets.
